[Prophylaxis of early radiation injuries to intact tissues following exposure to combined photon-neutron radiotherapy for malignant head and neck tumors].
Our data are presented on comparison of early- and late-response and complications in 320 patients with head and neck tumors after combined photon-neutron radiotherapy (CPNT) alone or in conjunction with cisplatin. Laser therapy via the LGN-222 quartz installation alternating with irradiation sessions was used to prevent and palliate radiation injuries. As a result, the incidence of acute (grade I-II) reactions was significantly lowered and severe fast-neutron-induced complications were avoided. Grade I (RTOG) skin and mucous membrane injuries were rarer in the main group receiving laser therapy (2.47%) as compared with controls (8.93%) (p < or = 0.02). Grade II injuries totaled 11.6% as compared with 5.57% in control (p < or = 0.02). No damage to skin and mucous membranes in grade III-IV (RTOG) was reported. Use of cisplatin was followed by a rise in frequency of both focal (90%) and diffuse (10%) film-coated membrane epithelite (p < or = 0.02). However, radiation-related response was aborted within 10-14 days after treatment in all cases. Our procedure may be used as a method of choice in prophylaxis of severe tissue damage and CPNT-induced complications.
A V
AV
Vazhenin
E Iu
EIu
Lukina
A I
AI
Kuznetsova
Z Z
ZZ
Munasipov
G V
GV
Mokichev
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D009502:Neutrons / Q000009:adverse effects* / Q000627:therapeutic use; D017785:Photons / Q000009:adverse effects* / Q000627:therapeutic use; D011832:Radiation Injuries / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D018714:Radiotherapy, Adjuvant; D012720:Severity of Illness Index; D013997:Time Factors
D000970:Antineoplastic Agents; D002945:Cisplatin